Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Co-Diagnostics (NASDAQ:CODX) Inc announced that CoSara Diagnostics Private Ltd, its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its SARAQ Hepatitis B (HBV) Viral Load Kit as an in vitro diagnostic (IVD).  CoSara's new real-time HBV PCR test is built on the company's patented CoPrimer technology and designed to be used as an aid in assessing response to antiviral treatments in patients diagnosed with HBV, a disease that leads to more than 800,000 deaths per year, according to the World Health Organization.

Co-Diagnostics says its joint venture CoSara receives clearance from Indian regulators from Hepatitis B viral load test

SALT LAKE CITY, Feb. 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAQ™ Hepatitis B (HBV) Viral Load Kit as an in vitro diagnostic ("IVD"). CoSara's new real-time HBV PCR test is built on the Company's patented CoPrimer™ technology and designed to be used as an aid in assessing response to antiviral treatments in patients diagnosed with HBV, a disease that leads to more than 800,000 deaths per year according to the World Health Organization ("WHO").

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis B Viral Load Test

Seeking Alpha's three ratings metrics have long awarded Co-Diagnostics top grades of "A+".

Co-Diagnostics: Swinging For The Fences

SALT LAKE CITY, Jan. 21, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming Medlab Middle East 2022 trade show held January 24-27 at the Dubai World Trade Centre. It is expected that the conference, catering to the global medical laboratory community and showcasing the latest in laboratory innovation and technology, will provide opportunities for Company representatives and distributors to introduce Co-Diagnostics products to a wide array of international customers.

Co-Diagnostics, Inc. to Host Booth at Medlab Middle East 2022 in Dubai on January 24-27

Co-Diagnostics Inc said its CoSara Diagnostics Pvt Ltd joint venture in India has received clearance from the Central Drugs Standard Control Organization (CDSCO) to manufacture and sell its SARAGENE Human Papillomavirus High-Risk (HPV-HR) Real-Time PCR test as an in vitro diagnostic (IVD). Human papillomavirus (HPV) is the most common sexually transmissible infection in the world and the cause of almost all cervical cancer worldwide (the 4th deadliest cancer in women), as well as a substantial portion of certain other cancers, totaling over 600,000 cases of cancer per year being attributable to HPV.

Co-Diagnostics says CoSara JV wins Indian regulatory clearance to sell its SARAGENE Human Papillomavirus High-Risk Real-Time PCR test

SALT LAKE CITY, Jan. 13, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAGENE™ Human Papillomavirus High-Risk (HPV-HR) Real-Time PCR test as an in vitro diagnostic ("IVD"). Human papillomavirus ("HPV") is the most common sexually transmissible infection in the world and the cause of almost all cervical cancer worldwide (the 4th deadliest cancer in women), as well as a substantial portion of certain other cancers, totaling over 600,000 cases of cancer per year being attributable to HPV.

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for High-Risk HPV Multiplex Test

SALT LAKE CITY, Jan. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be featured at the H.C. Wainwright & Co. 2022 BioConnect Conference, being held virtually on January 10-13.

Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 BioConnect Virtual Conference on January 10-13

Here is how CoDiagnostics, Inc. (CODX) and Cronos Group (CRON) have performed compared to their sector so far this year.

Has CoDiagnostics, Inc. (CODX) Outpaced Other Medical Stocks This Year?

Co-Diagnostics (NASDAQ:CODX) Inc announced that it has completed the acquisition of Idaho Molecular Inc and Advanced Conception Inc to provide the company with all existing and future assets and intellectual property related to its upcoming at-home/point-of-care diagnostic device. The transaction was settled for 4.72 million shares of Co-Diagnostics (NASDAQ:CODX) stock, and additional common warrants totaling 465,000.

Co-Diagnostics completes acquisition of Idaho Molecular and Advanced Conception to expand its at-home/point-of-care diagnostic device

SALT LAKE CITY, Dec. 31, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the acquisition of Idaho Molecular Inc. and Advanced Conceptions, Inc. for nearly 4.72 million shares of the Company's stock, plus additional common warrants totaling 465,000, providing Co-Diagnostics with all existing and future assets and intellectual property related to the Company's upcoming at-home/point-of-care diagnostic device. The acquisition, first announced on December 22 , is expected to streamline the commercialization of the Eikon™ platform and YourTest™ PCR device as it nears completion.

Co-Diagnostics, Inc. Announces Completion of the Acquisition of all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform

Ocugen, Inc.

Sorrento Therapeutics

Even with COVID-19 cases rising, the prospects for these stocks remain uncertain.

Why Co-Diagnostics, Ocugen, and Sorrento Stocks Are Sinking This Week

The molecular testing company is expected to benefit from the rise in cases of the omicron COVID-19 variant.

Why Co-Diagnostics Stock Rose 15.8% on Monday

Develops products to detect infectious diseases in humans and animals Offers Logix Smart coronavirus detection test in US and globally Amassed balance sheet of $72.4 million What Co-Diagnostics does:  Co-Diagnostics Inc is a molecular diagnostics company that develops products to detect infectious diseases in humans and animals. The company also develops tools for liquid-biopsy cancer screening and agricultural uses.

Co-Diagnostics fighting coronavirus (COVID-19) with flagship test, plans at-home PCR-based platform

Co-Diagnostics (NASDAQ:CODX) Inc announced that it has signed agreements to acquire Idaho Molecular Inc and Advance Conceptions Inc for the development of its upcoming at-home/point-of-care diagnostic device. The Utah-based company said that the transactions will provide it with all the existing and future assets and intellectual property related to the upcoming platform.

Co-Diagnostics signs agreement to acquire Idaho Molecular and Advanced Conception for its at-home/point-of-care platform

SALT LAKE CITY, Dec. 22, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has entered into definitive agreements with each of Idaho Molecular Inc. and Advanced Conceptions, Inc., pursuant to which each of them will become wholly owned subsidiaries of Co-Dx. Co-Dx has been working with Idaho Molecular and Advanced Conceptions on the development of Co-Diagnostics' upcoming at-home/point-of-care diagnostic device.

Co-Diagnostics, Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform

CVS Health

Kelly Services

Lowe's

NextEra Energy

QuidelOrtho Corp

Winnebago

With the omicron variant presenting uncertainties regarding how governments will react, here are some stocks to buy to counter that risk. The post 7 Stocks to Buy to Hedge Against Omicron Variant Risks appeared first on InvestorPlace.

7 Stocks to Buy to Hedge Against Omicron Variant Risks

Co-Diagnostics (NASDAQ:CODX) Inc said it has partnered with TiiCKER—a consumer shareholder loyalty platform—to increase its connection to retail investors.  The Salt Lake City-based company has teamed up with TiiCKER to reach new and existing investors, verify its shareholders and stock perks, and connect with retail investors interested in learning more about its world-class testing services and technology.

Co-Diagnostics partners with TiiCKER to increase connection with retail investors

SALT LAKE CITY, Dec. 7, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company that develops and manufactures state-of-the-art diagnostics technology used in over 50 countries, announced a partnership with TiiCKER™; a consumer shareholder loyalty platform, to increase its connection to retail investors. Co-Diagnostics is teaming with TiiCKER to reach new and existing investors, verify its shareholders and stock perks, and connect with retail investors interested in learning more about their world-class testing services and technology via www.TiiCKER.com/CODX.

Creator of COVID-19 and Global Molecular Testing Products Co-Diagnostics, Inc. Launches Retail Investor and Perks Program with TiiCKER

Co-Diagnostics (NASDAQ:CODX) Inc, has announced that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its SARAPLEX Flu A/Flu B/coronavirus (COVID-19) (ABC) RTPCR test as an in vitro diagnostic (IVD). The Salt Lake City, Utah-based molecular diagnostics company noted that CoSara's new test, the fourth CoSara assay to receive CDSCO approval this year and 11th overall, is built on the company's patented CoPrimer technology and designed for the simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2 (ABC).

Co-diagnostics JV CoSara receives clearance from Indian regulators for ABC Multiplex Test.

SALT LAKE CITY, Dec. 7, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Flu A/Flu B/COVID-19 (ABC) RT-PCR test as an in vitro diagnostic ("IVD"). CoSara's new test, the 4th CoSara assay to receive CDSCO approval this year and 11th overall, is built on the Company's patented CoPrimer™ technology and designed for the simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2.

Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for ABC Multiplex Test

Co-Diagnostics Inc. (NASDAQ:CODX) shares gapped higher Monday, but have since fallen and are now trading lower. The company said today its COVID-19 diagnostics are not affected by the omicron variant.

Co-Diagnostics Stock Sees Movement After Company Says Products Unaffected By Omicron Variant

Co-Diagnostics (NASDAQ:CODX) Inc., which has a patented platform for the development of molecular diagnostic tests, revealed that none of the mutations in the heavily mutated SARS-CoV-2 variant recently discovered in Africa are expected to interfere with any of its suite of coronavirus (COVID-19) PCR diagnostic assays. The Salt Lake City, Utah-based molecular diagnostics company said that the new coronavirus strain includes more than 50 mutations, over 30 of which are found on the virus's spike protein, the main target of the body's immune responses, and is currently being studied to determine whether the mutations lead to increased transmissibility, or ability to evade the body's immune response.

Co-Diagnostics says its suite of coronavirus diagnostics not affected by heavily mutated Omicron variant

SALT LAKE CITY, Nov. 29, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, reported today that none of the mutations in the heavily mutated SARS-CoV-2 variant recently discovered in Africa are predicted to interfere with any of the Company's suite of COVID-19 PCR diagnostic assays. None of the mutations in the Omicron variant interfere with any of the Company's COVID-19 PCR diagnostic assays The new coronavirus strain includes more than 50 mutations, over 30 of which are found on the virus's spike protein, the main target of the body's immune responses, and is currently being studied to determine whether the mutations lead to increased transmissibility or ability to evade the body's immune response.

Co-Diagnostics, Inc. Reports that Suite of COVID-19 Diagnostics Not Affected by Heavily Mutated Omicron Variant

SALT LAKE CITY, Nov. 15, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at the MEDICA 2021 trade fair in Düsseldorf, Germany from 15-18 November. The Fair is expected to include around 2,900 exhibitors from 70 countries, returning to an in-person trade show for the first time following the onset of the pandemic.

Co-Diagnostics, Inc. to Host Booth at MEDICA 2021 Trade Fair in Düsseldorf, Germany

The company absolutely crushed analysts' Q3 estimates.

News for Co-Diagnostics Stock (CODX)